Quris Technologies Ltd. has inked an agreement with Merck KGaA to assess its BioAI safety prediction platform. The partnership will compare the Quris’ artificial intelligence (AI)-based platform with traditional in vivo and in vitro approaches of evaluating drug safety concerns.
Mica Biosystems Ltd. is linking up with U.K. innovation center Cell and Gene Therapy Catapult (CGT Catapult) to accelerate commercialization of its regenerative technology platform. CGT Catapult is supporting the Birmingham, U.K.-based startup as it engages in conversations with the U.K.’s Medicines and Healthcare Products Regulatory Agency for clinical trials testing its remote-controlled stem cell therapy platform.
PARIS – An interdisciplinary academic research consortium in Italy has devised and tested nanowires that restore physiological cell-to-cell conductance. This research team, led by the Experimental and Applied Medical Technology Lab (Tecmed Lab) at the Department of Medicine and Surgery at the University of Parma, Italy, has just published the results of multiple local in situ injections of nanowires into left ventricular infarct regions in Nature Communications.
Investors have backed Oxford University spin-off ONI Ltd. with $75 million to push commercialization of its nanoimaging technology. The startup’s flagship product Nanoimager is a desktop, super resolution microscope capable of visualizing, tracking, and imaging individual molecules in living cells with 20 nm resolution. The technology is already in use with biomedical companies to aid development of more efficient, targeted therapies.
University of California San Diego engineers have developed tiny 2D sensors that pop up to become a 3D assemblage of microscopic sensors for directly measuring the movement and speed of electrical signals inside the heart. According to nanoengineering professor Sheng Xu, the nanotechnology has enormous implications for heart doctors anxious to better diagnose and treat arrhythmia, heart attack and other diseases.
PARIS – At some point, scientists reported, it may be possible to quarantine viruses rather than humans. For the last two years, European research consortium Virofight has been working on a form of nanotechnology intended to neutralize viruses such as SARS-CoV-2, HIV, influenza and hepatitis viruses.
Researchers from The Hong Kong Polytechnic University said they have used two-dimensional nanosheets to develop a biomimetic nanosheet that can monitor tumor development, treat tumors and monitor the treatment progress in real-time.
Researchers from The Hong Kong Polytechnic University (PolyU) said they have used two-dimensional nanosheets (FePSe3) to develop a biomimetic nanosheet that can monitor tumor development, treat tumors and monitor the treatment progress in real-time. With positive results from mice, the team hopes to further test it on larger animals, then move on to clinical studies.
Following steady expansion of its base among global pharmaceutical companies, Correlia Biosystems Inc. has secured the capital needed to make its nanotechnology-based immunoassay platform commercially available. The company received an infusion of $7 million in series A financing in a round led by Neotribe Ventures with participation by Cota Capital, the Regents of the University of California and others.
PARIS – Curadigm SAS has raised $1 million in non-dilutive funding from Bpifrance (Banque publique d’investissement in France), for development of its Nanoprimer technology. Bpifrance’s Deep Tech program in France recognizes health tech companies with breakthrough innovation and strong commercial potential.